Cargando…
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital
OBJECTIVE: This study aims to analyze the impact of the eOncosalud app on the management and follow-up of adverse effects (AE) in patients receiving oral antineoplastic agents. MATERIAL AND METHODS: We performed an observational, prospective study of cancer outpatients treated with oral antineoplast...
Autores principales: | Villanueva-Bueno, Cristina, Collado-Borrell, Roberto, Escudero-Vilaplana, Vicente, Revuelta-Herrero, José Luis, Marzal-Alfaro, María Belén, González-Haba, Eva, Arranz-Arija, José Ángel, Osorio, Santiago, Herranz-Alonso, Ana, Sanjurjo-Saez, María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672512/ https://www.ncbi.nlm.nih.gov/pubmed/36407983 http://dx.doi.org/10.3389/fpubh.2022.978783 |
Ejemplares similares
-
Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
por: Marzal-Alfaro, María Belen, et al.
Publicado: (2021) -
Features and Functionalities of Smartphone Apps Related to COVID-19: Systematic Search in App Stores and Content Analysis
por: Collado-Borrell, Roberto, et al.
Publicado: (2020) -
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App
por: Escudero-Vilaplana, Vicente, et al.
Publicado: (2022) -
Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey
por: Collado-Borrell, Roberto, et al.
Publicado: (2018) -
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy
por: Ramos-Ruperez, Elena, et al.
Publicado: (2023)